Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Charming Medical's Debt-to-EBITDA or its related term are showing as below:
MCTA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -9.57 Med: 0.68 Max: 0.68
Current: 0.53
During the past 3 years, the highest Debt-to-EBITDA Ratio of Charming Medical was 0.68. The lowest was -9.57. And the median was 0.68.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Charming Medical Debt-to-EBITDA Related Terms
Charming Medical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Charming Medical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MCTA vs EHAB, CYH, SRTA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Charming Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charming Medical Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Charming Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Charming Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Sep. 2025) EBITDA data.
Charming Medical (MCTA) has a Debt-to-EBITDA of 3.05 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Charming Medical. This is 349% above median its historical median of 0.68.
Is Charming Medical's Debt-to-EBITDA too high?
Charming Medical's current Debt-to-EBITDA of 3.05 is 349% above median its 10-year median of 0.68. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. Charming Medical's value of 3.05 is 35.6% above this industry median. Overall, Charming Medical has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Charming Medical's Debt-to-EBITDA compare to EHAB and CYH?
Charming Medical's Debt-to-EBITDA of 3.05 can be compared against companies in the Healthcare Providers & Services industry. The industry median Debt-to-EBITDA is 2.25. Charming Medical's value of 3.05 is 35.6% above this benchmark. While the company's 10-year median is 0.68 vs. the industry median of 2.25, Charming Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charming Medical's current Debt-to-EBITDA of 3.05 is 35.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Charming Medical. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charming Medical's current Debt-to-EBITDA is 3.05, which is 349% above median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charming Medical stock overvalued right now?
Charming Medical (MCTA) has a current Debt-to-EBITDA of 3.05. The current Debt-to-EBITDA is 3.05, which is 349% above median its 10-year median of 0.68 and 35.6% above the Healthcare Providers & Services industry median of 2.25. Charming Medical's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Charming Medical (MCTA), the current Debt-to-EBITDA is 3.05 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address2-20 Paterson Street, Causeway Bay, Units 1803-1806, 18th Floor, Hang Lung Centre, Hong Kong, HKG
Charming Medical Ltd is a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. It offers a wide range of beauty, wellness, and postpartum services and products rooted and influenced by the principles and practices of TCM, such as the use of herbal ingredients, acupuncture techniques, Tuina massage, and dietary guidance. Its beauty, wellness, and postpartum services include but are not limited to womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, TCM-inspired prenatal massage, and Indonesian traditional abdominal binding.
29GF Score
Get the complete analysis for MCTA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MCTA has been successfully added to your 
